TY - JOUR
T1 - Restricted T-Cell Repertoire in the Epicardial Adipose Tissue of Non-ST Segment Elevation Myocardial Infarction Patients
AU - Pedicino, Daniela
AU - Severino, Anna
AU - Di Sante, Gabriele
AU - De Rosa, Maria Cristina
AU - Pirolli, Davide
AU - Vinci, Ramona
AU - Pazzano, V.
AU - Giglio, A. F.
AU - Trotta, F.
AU - Russo, G.
AU - Ruggio, A.
AU - Pisano, Eugenia
AU - D'Aiello, Alessia
AU - Canonico, Francesco
AU - Ciampi, P.
AU - Cianflone, D.
AU - Cianfanelli, L.
AU - Grimaldi, Maria Chiara
AU - Filomia, Simone
AU - Luciani, Nicola
AU - Glieca, Franco
AU - Bruno, Piergiorgio
AU - Massetti, Massimo
AU - Ria, Francesco
AU - Crea, Filippo
AU - Liuzzo, Giovanna
PY - 2022
Y1 - 2022
N2 - Aims: Human epicardial adipose tissue, a dynamic source of multiple bioactive factors, holds a close functional and anatomic relationship with the epicardial coronary arteries and communicates with the coronary artery wall through paracrine and vasocrine secretions. We explored the hypothesis that T-cell recruitment into epicardial adipose tissue (EAT) in patients with non-ST segment elevation myocardial infarction (NSTEMI) could be part of a specific antigen-driven response implicated in acute coronary syndrome onset and progression. Methods and Results: We enrolled 32 NSTEMI patients and 34 chronic coronary syndrome (CCS) patients undergoing coronary artery bypass grafting (CABG) and 12 mitral valve disease (MVD) patients undergoing surgery. We performed EAT proteome profiling on pooled specimens from three NSTEMI and three CCS patients. We performed T-cell receptor (TCR) spectratyping and CDR3 sequencing in EAT and peripheral blood mononuclear cells of 29 NSTEMI, 31 CCS, and 12 MVD patients. We then used computational modeling studies to predict interactions of the TCR beta chain variable region (TRBV) and explore sequence alignments. The EAT proteome profiling displayed a higher content of pro-inflammatory molecules (CD31, CHI3L1, CRP, EMPRINN, ENG, IL-17, IL-33, MMP-9, MPO, NGAL, RBP-4, RETN, VDB) in NSTEMI as compared to CCS (P < 0.0001). CDR3-beta spectratyping showed a TRBV21 enrichment in EAT of NSTEMI (12/29 patients; 41%) as compared with CCS (1/31 patients; 3%) and MVD (none) (ANOVA for trend P < 0.001). Of note, 11/12 (92%) NSTEMI patients with TRBV21 perturbation were at their first manifestation of ACS. Four patients with the first event shared a distinctive TRBV21-CDR3 sequence of 178 bp length and 2/4 were carriers of the human leukocyte antigen (HLA)-A*03:01 allele. A 3D analysis predicted the most likely epitope able to bind HLA-A3*01 and interact with the TRBV21-CDR3 sequence of 178 bp length, while the alignment results were consistent with microbial DNA sequences. Conclusions: Our study revealed a unique immune signature of the epicardial adipose tissue, which led to a 3D modeling of the TCRBV/peptide/HLA-A3 complex, in acute coronary syndrome patients at their first event, paving the way for epitope-driven therapeutic strategies.
AB - Aims: Human epicardial adipose tissue, a dynamic source of multiple bioactive factors, holds a close functional and anatomic relationship with the epicardial coronary arteries and communicates with the coronary artery wall through paracrine and vasocrine secretions. We explored the hypothesis that T-cell recruitment into epicardial adipose tissue (EAT) in patients with non-ST segment elevation myocardial infarction (NSTEMI) could be part of a specific antigen-driven response implicated in acute coronary syndrome onset and progression. Methods and Results: We enrolled 32 NSTEMI patients and 34 chronic coronary syndrome (CCS) patients undergoing coronary artery bypass grafting (CABG) and 12 mitral valve disease (MVD) patients undergoing surgery. We performed EAT proteome profiling on pooled specimens from three NSTEMI and three CCS patients. We performed T-cell receptor (TCR) spectratyping and CDR3 sequencing in EAT and peripheral blood mononuclear cells of 29 NSTEMI, 31 CCS, and 12 MVD patients. We then used computational modeling studies to predict interactions of the TCR beta chain variable region (TRBV) and explore sequence alignments. The EAT proteome profiling displayed a higher content of pro-inflammatory molecules (CD31, CHI3L1, CRP, EMPRINN, ENG, IL-17, IL-33, MMP-9, MPO, NGAL, RBP-4, RETN, VDB) in NSTEMI as compared to CCS (P < 0.0001). CDR3-beta spectratyping showed a TRBV21 enrichment in EAT of NSTEMI (12/29 patients; 41%) as compared with CCS (1/31 patients; 3%) and MVD (none) (ANOVA for trend P < 0.001). Of note, 11/12 (92%) NSTEMI patients with TRBV21 perturbation were at their first manifestation of ACS. Four patients with the first event shared a distinctive TRBV21-CDR3 sequence of 178 bp length and 2/4 were carriers of the human leukocyte antigen (HLA)-A*03:01 allele. A 3D analysis predicted the most likely epitope able to bind HLA-A3*01 and interact with the TRBV21-CDR3 sequence of 178 bp length, while the alignment results were consistent with microbial DNA sequences. Conclusions: Our study revealed a unique immune signature of the epicardial adipose tissue, which led to a 3D modeling of the TCRBV/peptide/HLA-A3 complex, in acute coronary syndrome patients at their first event, paving the way for epitope-driven therapeutic strategies.
KW - Acute Coronary Syndrome
KW - Adipose Tissue
KW - Epitopes
KW - HLA-A3 Antigen
KW - Humans
KW - Leukocytes, Mononuclear
KW - NSTE ACS
KW - Non-ST Elevated Myocardial Infarction
KW - Proteome
KW - T-Lymphocytes
KW - T-cell receptor (TCR)
KW - antigen-driven immunity
KW - computational modeling
KW - epicardial adipose tissue (EAT)
KW - first acute myocardial infarction
KW - immune response
KW - precision medicine
KW - Acute Coronary Syndrome
KW - Adipose Tissue
KW - Epitopes
KW - HLA-A3 Antigen
KW - Humans
KW - Leukocytes, Mononuclear
KW - NSTE ACS
KW - Non-ST Elevated Myocardial Infarction
KW - Proteome
KW - T-Lymphocytes
KW - T-cell receptor (TCR)
KW - antigen-driven immunity
KW - computational modeling
KW - epicardial adipose tissue (EAT)
KW - first acute myocardial infarction
KW - immune response
KW - precision medicine
UR - http://hdl.handle.net/10807/219308
U2 - 10.3389/fimmu.2022.845526
DO - 10.3389/fimmu.2022.845526
M3 - Article
SN - 1664-3224
VL - 13
SP - N/A-N/A
JO - Frontiers in Immunology
JF - Frontiers in Immunology
ER -